incretins

News

Novo turns to Hengrui for another oral obesity drug

Novo has agreed to pay up to $2.6 billion for rights to a weight-loss pill, developed by China's Hengrui Pharma, that could be dosed just once a week.

News

Novo Nordisk's IL-6 drug flunks two more heart trials

Novo Nordisk has opted to discontinue two late-stage trials of IL-6 inhibitor ziltivekimab in heart failure, after taking an interim look at the data.

News

Business Group on Health statistics graphic

As drug costs for US employers rise, some cut GLP-1s from pl...

Pharmacy now represents 25% of employer healthcare spending, and employers are turning to DTC models and non-traditional PBMs to cut costs.

News

Lilly sues over 'illegal sales' of obesity drug retatrutide

Eli Lilly has sued six US-based companies it accuses of participating in an illegal black market for experimental weight-loss drug retatrutide.

News

Novo Nordisk wins Netherlands GLP-1 compounding lawsuit

A Dutch compounding pharmacy has been ordered to stop distributing a compounded nasal spray version of Novo Nordisk's GLP-1 agonist semaglutide.

News

A man drunken on vodka lies in the grass

Altimmune alcohol use disorder drug hits the mark in phase 2

Altimmune's pemvidutide has been shown to reduce drinking in people with alcohol use disorder, adding to the evidence for GLP-1 drugs in this setting.

incretins

Editor's Picks